[评论] 瑞他鲁肽在肥胖合并2型糖尿病成人中的应用：我们从TRIUMPH-2中了解了什么？
摘要
普遍观察到，使用GLP-1受体激动剂所获得的体重减轻程度，在2型糖尿病患者中低于无糖尿病且BMI相似的人群。这种差异能否被具有更强减重效果的新型三重激动剂所克服？Virginia Bellido及其同事1在《柳叶刀》上发表的TRIUMPH-2研究，是一项双盲、平行分组、随机、安慰剂对照的3期试验，评估了瑞他鲁肽（一种三重激动剂，作用于GLP-1、GIP和胰高血糖素）在肥胖合并2型糖尿病患者中的效果。
English
It is a general observation that the degree of weight loss obtained with GLP-1 receptor agonists is less in individuals with type 2 diabetes than in people without diabetes and similar BMI. Could this difference be overcome with the new triple agonists with superior weight-lowering effects? The TRIUMPH-2 study by Virginia Bellido and colleagues1 in The Lancet is a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial of the effects of retatrutide, a triple agonist (GLP-1, GIP, and glucagon), in people with obesity and type 2 diabetes.